Navigation Links
Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018
Date:5/26/2009

Emerging Novel Oral Therapies Will Garner 29 Percent of the Total Market in 2018, According to a New Report from Decision Resources

WALTHAM, Mass., May 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the approval and launch of highly anticipated oral agents as well as the increasing use of current and emerging injectable drugs will drive the overall multiple sclerosis drug market to nearly $10 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Multiple Sclerosis finds that emerging novel oral therapies, most notably Merck Serono/EMD Serono's oral cladribine and Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), will garner 29 percent of the total multiple sclerosis market in 2018. Oral cladribine and FTY-720 will together capture more than $2 billion in major market sales in 2018, despite safety concerns associated with both drugs. The report also finds that three additional emerging agents - Biogen Idec's pegylated interferon-beta-1a, Genzyme/Bayer Schering/Bayer HealthCare's alemtuzumab (currently marketed as Campath/MabCampath) and BioMS Medical/Eli Lilly's dirucotide - will also contribute substantially to market growth by providing new therapeutic options to patients.

"Owing to the multitude of emerging therapies in late stage development, each of which offers particular attributes, and because combination treatment in multiple sclerosis is rare, the market will become increasingly fragmented as current and emerging therapies vie for niche patient populations," said Decision Resources Analyst Bethany Kiernan, Ph.D. "Nevertheless, the need for efficacious, safe and/or convenient therapies will permit all agents--including those that show robust efficacy but bear serious safety risks--to fulfill crucial needs among patie
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3
...supplement no substitute for old-fashioned hard wo...ay News) -- Taking creatine doesn,t improve exerci... pulmonary disease (COPD), a U.K. study reports. ...eived either creatine or a placebo during a seven-...
... Mark Merritt, President,of the Pharmaceutical Ca...atement in response to new comparative effectivene... Finance Committee Chair Max Baucus,(D-Mont.) and ...ove quality through more objective,information and...
...ther treating the breathing disorder cuts the dang...althDay News) -- The interrupted nighttime breathi...dying, Australian researchers report. , Earlier st...s new study suggests that the risk is present amon...
...searchers at the University of Pennsylvania School... FOXA2 controls genes that maintain the proper lev...s for new therapies to treat diseases that involve...ll bladder and transported through ducts to the sm...
... Vertrue, for the second year in a row, is g...o families and children who need it the most. , ...1, 2008 -- For the second year in a row, http://w...ry of Vertrue, are giving away $1 million in disco...
... For the second consecutive year, Omega Inst...nebeck campus August 15-17, for professionals and ...plore the latest research and development in treat...host an important conference at its Rhinebeck camp...
Other Medicine News:Health News:Creatine Has Negligible Effect on COPD Exercise Rehab 2Health News:Sleep Apnea Boosts Death Risk 2Health News:Sleep Apnea Boosts Death Risk 3Health News:Penn researchers find a new role for a 'Foxy Old Gene' 2Health News:Vertrue Incorporated and Feed The Children Join Forces to Give Away $1 Million in Aid to Families in Need 2Health News:Vertrue Incorporated and Feed The Children Join Forces to Give Away $1 Million in Aid to Families in Need 3Health News:Vertrue Incorporated and Feed The Children Join Forces to Give Away $1 Million in Aid to Families in Need 4Health News:Omega to Hold Conference: Autism Through the Life Span II 2Health News:Omega to Hold Conference: Autism Through the Life Span II 3
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
(Date:12/3/2009)SAN DIEGO, Dec. 3 BioMed Realty Trust, Inc. (NYSE: BMR ) announced today that it has entered into a new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) for approximately 131,000 square
(Date:12/3/2009)FORT WORTH, Texas, Dec. 3 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health In
Breaking Medicine Technology:Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3Prime Retail Launches Operation Shop Pink 56749 1Prime Retail Launches Operation Shop Pink 56749 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 1Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 4Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 1Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 2Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 3Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 4
...ll to be held on Wednesday, August 6, 2008 at 8:00...., Aug. 5 Isolagen(TM), Inc. (Amex:,ILE) announce...lts from two,pivotal, Phase III clinical studies (...rapy(TM) for the treatment of nasolabial folds, or...ial Protocol Assessment (SPA), met,all primary end...
... Nexgen Spine, a leading,developer of innovative ...nerative disc disease, announced today that it has...R) Lumbar Artificial Disc in the European,Union., ... Disc Prosthesis has,received CE mark approval," s...exgen Spine. "This represents an important milesto...
Other Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
Broncho-Cath® Endobronchial Tube with CPAP System
...made of silicone rubber with a wire reinforced end... of silicone rubber, Silbronco is soft and less tr...the tube will not soften like PVC tubes, which mak...lbronco is also especially useful when a tumor lif...
Portex Pedia-Trake® Pediatric Emergency Cricothyrotomy Kit
Melker Emergency Cricothyrotomy Catheter Sets
Medicine Products: